Matrix-M1 Adjuvant

BIOLOGICAL2 trials

Sponsors

Novavax, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Epstein-Barr Virus InfectionHerpesvirusInfectious MononucleosisRespiratory Syncytial Viruses

Phase 1

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Active, not recruitingNCT05683834

National Institute of Allergy and Infectious Diseases (NIAID)Epstein-Barr Virus Infection, Herpesvirus, Infectious Mononucleosis

Start: 2023-09-22End: 2027-04-01Updated: 2025-11-21

Phase 2

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

CompletedNCT03026348

NovavaxRespiratory Syncytial Viruses

Start: 2017-01-31End: 2018-05-18Updated: 2021-12-06